Global Genetic Testing Market Forecast to 2015
“Global Genetic Testing Market Forecast to 2015”, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principal, types and Direct-to-Consumer (DTC) business methodology is also covered in around 95-page report. On account of our analysis of the past and present market trends, drivers, and existing strengths and challenges, forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 26% during 2012-2015.
The report effectively illustrates the role of genetic testing in diseases, such as Cancer, Cystic Fibrosis, and Alzheimer’s. It also incorporates the information on disease prevalence, available tests, and genes responsible/discovered that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely: Next-Generation Sequencing and Genomic Biomarkers are found inside the report.
The report provides comprehensive analytics of key developments for major markets including the US, Canada, the UK, and Germany. These key developments are likely to set the future of genetic testing market in these countries and that is precisely the reason behind their incorporation in the report.
The report also profiles the eight most active genetic testing market players worldwide: Abbott Laboratories, Beckman Coulter, Roche Diagnostics, Myriad Genetics, Life Technologies, Genomic Health, Sequenom and Transgenomic. For the purpose of effective competitive analysis of the market, these companies are analyzed on five major areas namely: business overview, product offering; financial performance for the last three years, strategic analysis of strengths and weaknesses and key developments.
The report effectively illustrates the role of genetic testing in diseases, such as Cancer, Cystic Fibrosis, and Alzheimer’s. It also incorporates the information on disease prevalence, available tests, and genes responsible/discovered that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely: Next-Generation Sequencing and Genomic Biomarkers are found inside the report.
The report provides comprehensive analytics of key developments for major markets including the US, Canada, the UK, and Germany. These key developments are likely to set the future of genetic testing market in these countries and that is precisely the reason behind their incorporation in the report.
The report also profiles the eight most active genetic testing market players worldwide: Abbott Laboratories, Beckman Coulter, Roche Diagnostics, Myriad Genetics, Life Technologies, Genomic Health, Sequenom and Transgenomic. For the purpose of effective competitive analysis of the market, these companies are analyzed on five major areas namely: business overview, product offering; financial performance for the last three years, strategic analysis of strengths and weaknesses and key developments.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INTRODUCTION TO GENETIC TESTING
4. GLOBAL GENETIC TESTING MARKET OVERVIEW
4.1 Market Outlook
4.2 Genetic Testing Laboratories - Unmet Need Analysis
4.3 DTC Genetic Testing
5. DISEASE-WISE ANALYSIS
5.1 Alzheimer's Disease
5.2 Cystic Fibrosis
5.3 Cancer
6. COUNTRY-LEVEL ANALYSIS
6.1 US
6.1.1 Companion Diagnostics and LDTs
6.1.2 Economical and Social Impact
6.1.3 Regulatory Measures
6.1.4 Research and Studies
6.2 Canada
6.2.1 World's First Bedside Genetic Test
6.2.2 Physicians’ Opinion
6.2.3 Information Privacy
6.3 UK
6.3.1 Role of NICE
6.3.2 Newborn Screening: Five Rare Inherited Diseases
6.4 Germany
6.4.1 Pre-implantation Genetic Diagnosis
6.4.2 RAD51C Mutation Screening
7. EMERGING SECTORS
7.1 Next-Generation Sequencing
7.2 Genomic Biomarkers
8. COMPETITIVE ASSESSMENT
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Product Offering
8.1.3 Financial Overview
8.1.4 Key Activities
8.1.5 Strengths & Weaknesses
8.2 Beckman Coulter
8.2.1 Company Overview
8.2.2 Product Offering
8.2.3 Financial Overview
8.2.4 Key Activities
8.2.5 Strengths & Weaknesses
8.3 Roche Diagnostics
8.3.1 Company Overview
8.3.2 Product Offering
8.3.3 Financial Overview
8.3.4 Key Activities
8.3.5 Strengths & Weaknesses
8.4 Myriad Genetics
8.4.1 Company Overview
8.4.2 Product Offering
8.4.3 Financial Overview
8.4.4 Key Activities
8.4.5 Strengths & Weaknesses
8.5 Life Technologies Corporation
8.5.1 Company Overview
8.5.2 Product Offering
8.5.3 Financial Overview
8.5.4 Key Activities
8.5.5 Strengths & Weaknesses
8.6 Genomic Health
8.6.1 Company Overview
8.6.2 Product Offering
8.6.3 Financial Overview
8.6.4 Key Activities
8.6.5 Strengths & Weaknesses
8.7 Sequenom
8.7.1 Company Overview
8.7.2 Product Offering
8.7.3 Financial Overview
8.7.4 Key Activities
8.7.5 Strengths & Weaknesses
8.8 Transgenomic
8.8.1 Company Overview
8.8.2 Product Offering
8.8.3 Financial Overview
8.8.4 Key Activities
8.8.5 Strengths & Weaknesses
2. RESEARCH METHODOLOGY
3. INTRODUCTION TO GENETIC TESTING
4. GLOBAL GENETIC TESTING MARKET OVERVIEW
4.1 Market Outlook
4.2 Genetic Testing Laboratories - Unmet Need Analysis
4.3 DTC Genetic Testing
5. DISEASE-WISE ANALYSIS
5.1 Alzheimer's Disease
5.2 Cystic Fibrosis
5.3 Cancer
6. COUNTRY-LEVEL ANALYSIS
6.1 US
6.1.1 Companion Diagnostics and LDTs
6.1.2 Economical and Social Impact
6.1.3 Regulatory Measures
6.1.4 Research and Studies
6.2 Canada
6.2.1 World's First Bedside Genetic Test
6.2.2 Physicians’ Opinion
6.2.3 Information Privacy
6.3 UK
6.3.1 Role of NICE
6.3.2 Newborn Screening: Five Rare Inherited Diseases
6.4 Germany
6.4.1 Pre-implantation Genetic Diagnosis
6.4.2 RAD51C Mutation Screening
7. EMERGING SECTORS
7.1 Next-Generation Sequencing
7.2 Genomic Biomarkers
8. COMPETITIVE ASSESSMENT
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Product Offering
8.1.3 Financial Overview
8.1.4 Key Activities
8.1.5 Strengths & Weaknesses
8.2 Beckman Coulter
8.2.1 Company Overview
8.2.2 Product Offering
8.2.3 Financial Overview
8.2.4 Key Activities
8.2.5 Strengths & Weaknesses
8.3 Roche Diagnostics
8.3.1 Company Overview
8.3.2 Product Offering
8.3.3 Financial Overview
8.3.4 Key Activities
8.3.5 Strengths & Weaknesses
8.4 Myriad Genetics
8.4.1 Company Overview
8.4.2 Product Offering
8.4.3 Financial Overview
8.4.4 Key Activities
8.4.5 Strengths & Weaknesses
8.5 Life Technologies Corporation
8.5.1 Company Overview
8.5.2 Product Offering
8.5.3 Financial Overview
8.5.4 Key Activities
8.5.5 Strengths & Weaknesses
8.6 Genomic Health
8.6.1 Company Overview
8.6.2 Product Offering
8.6.3 Financial Overview
8.6.4 Key Activities
8.6.5 Strengths & Weaknesses
8.7 Sequenom
8.7.1 Company Overview
8.7.2 Product Offering
8.7.3 Financial Overview
8.7.4 Key Activities
8.7.5 Strengths & Weaknesses
8.8 Transgenomic
8.8.1 Company Overview
8.8.2 Product Offering
8.8.3 Financial Overview
8.8.4 Key Activities
8.8.5 Strengths & Weaknesses
LIST OF FIGURES
Figure 4-1: Molecular Diagnostics Market (Billion US$), 2008-2011
Figure 4-2: Genetic Testing Market (Billion US$), 2008-2011
Figure 4-3: Forecast for Molecular Diagnostics Market (Billion US$), 2012-2015
Figure 4-4: Forecast for Genetic Testing Market (Billion US$), 2012-2015
Figure 4-5: Number of Companies in Biochemical DTC Genetic Testing Segment (2007-2010)
Figure 4-6: Number of DTC Genetic Testing Companies by Country
Figure 6-1: Number of Laboratories and Diseases for Genetic Testing (1993-2010)
Figure 8-1: Global - Next Generation Sequencing Market (Billion US$), 2011-2015
Figure 8-2: Global - NGS Application by Sector (%)
Figure 8-3: Global - Next Generation Sequencing Market by Player (%), 2010
Figure 4-1: Molecular Diagnostics Market (Billion US$), 2008-2011
Figure 4-2: Genetic Testing Market (Billion US$), 2008-2011
Figure 4-3: Forecast for Molecular Diagnostics Market (Billion US$), 2012-2015
Figure 4-4: Forecast for Genetic Testing Market (Billion US$), 2012-2015
Figure 4-5: Number of Companies in Biochemical DTC Genetic Testing Segment (2007-2010)
Figure 4-6: Number of DTC Genetic Testing Companies by Country
Figure 6-1: Number of Laboratories and Diseases for Genetic Testing (1993-2010)
Figure 8-1: Global - Next Generation Sequencing Market (Billion US$), 2011-2015
Figure 8-2: Global - NGS Application by Sector (%)
Figure 8-3: Global - Next Generation Sequencing Market by Player (%), 2010
LIST OF TABLES
Table 4-1: Genetic Testing Labs Penetration in Key Countries
Table 4-2: Key Companies in DTC Genetic Testing Segment
Table 5-1: Test Availability and Market Size for Key Conditions
Table 7-1: Listed Pharmacogenomic Biomarkers in FDA Approved Cancer Therapy Labels
Table 9-1: Abbott Molecular - Key Gene Based Product(s)
Table 9-2: Abbott Laboratories - Financial Performance (Million US$), 2009-2011
Table 9-3: Beckman Coulter - Key Gene Based Product(s)
Table 9-4: Beckman Coulter - Financial Performance (Million US$), 2008-2010
Table 9-5: Roche Molecular Diagnostics - Key Gene Based Product(s)
Table 9-6: Roche Holding - Financial Performance (Million US$), 2009-2011
Table 9-7: Myriad Genetics - Key Gene Based Product(s)
Table 9-8: Myriad Genetics - Financial Performance (Million US$), 2009-2011
Table 9-9: Life Technologies - Key Gene Based Product(s)
Table 9-10: Life Technologies - Financial Performance (Million US$), 2009-2011
Table 9-11: Genomic Health - Key Gene Based Product(s)
Table 9-12: Genomic Health - Financial Performance (Million US$), 2009-2011
Table 9-13: Sequenom - Key Gene Based Product(s)
Table 9-14: Sequenom - Financial Performance (Million US$), 2009-2011
Table 9-15: Transgenomic - Financial Performance (Million US$), 2009-2011
Table 4-1: Genetic Testing Labs Penetration in Key Countries
Table 4-2: Key Companies in DTC Genetic Testing Segment
Table 5-1: Test Availability and Market Size for Key Conditions
Table 7-1: Listed Pharmacogenomic Biomarkers in FDA Approved Cancer Therapy Labels
Table 9-1: Abbott Molecular - Key Gene Based Product(s)
Table 9-2: Abbott Laboratories - Financial Performance (Million US$), 2009-2011
Table 9-3: Beckman Coulter - Key Gene Based Product(s)
Table 9-4: Beckman Coulter - Financial Performance (Million US$), 2008-2010
Table 9-5: Roche Molecular Diagnostics - Key Gene Based Product(s)
Table 9-6: Roche Holding - Financial Performance (Million US$), 2009-2011
Table 9-7: Myriad Genetics - Key Gene Based Product(s)
Table 9-8: Myriad Genetics - Financial Performance (Million US$), 2009-2011
Table 9-9: Life Technologies - Key Gene Based Product(s)
Table 9-10: Life Technologies - Financial Performance (Million US$), 2009-2011
Table 9-11: Genomic Health - Key Gene Based Product(s)
Table 9-12: Genomic Health - Financial Performance (Million US$), 2009-2011
Table 9-13: Sequenom - Key Gene Based Product(s)
Table 9-14: Sequenom - Financial Performance (Million US$), 2009-2011
Table 9-15: Transgenomic - Financial Performance (Million US$), 2009-2011
